GeneBasket Secures Second Place in the 8th Zhongguancun International Frontier Tech Competition – Biopharma Track

Dec 27, 2024 11:45 CST Updated 11:45

Genecradle

Gene Therapy Drug Developer

Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Comments pointing out any inaccuracies are welcome. This article is only an introduction to pharmaceuticals related to healthcare and is not a recommendation of treatment plans (if involved). This article does not constitute any investment advice.

On December 25, the Eighth Zhongguancun International Frontier Technology Competition – Biomedical Field concluded successfully at Zhongguancun Dongsheng International Science Park. After fierce competition and evaluation, Beijing Genecradle Therapeutics Co., Ltd. stood out with its "Disruptive Gene Therapy Platform Technology Project for Critical Genetic Diseases in Children," successfully entering the top 10 list in the biomedical field and winning second place in this competition.

Zhongguan Village International Frontier Technology Competition is a high-level international competition platform jointly organized by the Beijing Municipal Science and Technology Commission, the Zhongguan Village Science Park Management Committee, and the Zhongguan Village Science City Management Committee. The event seeks the world's most impressive hard technologies through "global invitations, free exploration, and public roadshows," selecting companies and teams with internationally leading frontier technologies to create a high-level platform for displaying and exchanging cutting-edge technologies.

Genecradle's outstanding performance in this competition not only showcased its deep technical accumulation and strong innovative capabilities in the field of gene therapy but also highlighted its responsibility and mission as a biopharmaceutical enterprise. In the future, Genecradle will continue to uphold the spirit of innovation and pragmatism, further advance technology research and development, expand application areas, and bring hope and good news to more patients with genetic diseases.

Dr. Qianyi Wang, Head of Public Affairs at Genecradle, represented the team in the competition.

About Genecradle

Beijing Genecradle Therapeutics Co., Ltd. is a national high-tech enterprise with a core focus on the development of gene therapy drugs mediated by AAV vector delivery technology. Committed to advancing China’s rare disease gene therapies from foundational research to clinical and market applications, the company aims to benefit patients and their families. It specializes in the development of gene therapies for hereditary neuromuscular diseases, inherited metabolic disorders, lysosomal diseases, and ophthalmic conditions. By promoting the research, development, and clinical application of rare disease gene drugs, the company seeks to deepen the understanding of life and health while transitioning gene therapy technologies and products from rare diseases to the treatment and rehabilitation of chronic and other major diseases.

Source of the article:Genecradle